EyePoint Pharmaceuticals
EYPT
EYPT
151 hedge funds and large institutions have $508M invested in EyePoint Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 64 increasing their positions, 45 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
43% less call options, than puts
Call options by funds: $6.89M | Put options by funds: $12.1M
55% less capital invested
Capital invested by funds: $1.14B → $508M (-$629M)
Holders
151
Holding in Top 10
3
Calls
$6.89M
Puts
$12.1M
Top Buyers
| 1 | +$12.5M | |
| 2 | +$12.3M | |
| 3 | +$8.5M | |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$8.02M |
| 5 |
Morgan Stanley
New York
|
+$7.92M |
Top Sellers
| 1 | -$19.4M | |
| 2 | -$12.8M | |
| 3 | -$12.1M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$9.92M |